Molecular Determinants of Decitabine Response in Chronic Myelomonocytic Leukemia

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable, with few means to predict which patients will benefit. Here, we examined baseline differences in mutations, DNA methyla...

متن کامل

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Hydroxyurea is the standard therapy of chronic myelomonocytic leukemia (CMML) presenting with advanced myeloproliferative and/or myelodysplastic features. Response to hypomethylating agents has been reported in heterogeneous series of CMML. We conducted a phase 2 trial of decitabine (DAC) in 39 patients with advanced CMML defined according to a previous trial. Median number of DAC cycles was 10...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial

*Thorsten Braun,1 *Raphael Itzykson,1,2 Aline Renneville,3 Benoit de Renzis,4 François Dreyfus,5 Kamel Laribi,6 Krimo Bouabdallah,7 Norbert Vey,8 Andrea Toma,9 Christian Recher,10 Bruno Royer,11 Bertrand Joly,12 Anne Vekhoff,13 Ingrid Lafon,14 Laurence Sanhes,15 Guillaume Meurice,2 Cédric Oréar,2 Claude Preudhomme,3 Claude Gardin,1 Lionel Ades,1 Michaela Fontenay,16 Pierre Fenaux,1 Nathalie Dro...

متن کامل

Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia

According to the 2008 World Health Organization classification, chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia are rare diseases. The remarkable progress in our understanding of the molecular genetics of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms has made it clear that there are some specific genetic abnorm...

متن کامل

Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.

Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare entities grouped into the World Health Organisation (WHO) categories myeloproliferative and myelodysplastic/myeloproliferative neoplasms (MPN and MDS/MPN overlap), respectively. According to the WHO 2008 classification, both entities are characterized by leukocytosis and a hypercellular bone marrow, predom...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Blood

سال: 2014

ISSN: 0006-4971,1528-0020

DOI: 10.1182/blood.v124.21.4644.4644